It is interesting because PTCL and CTCL are the main subsets of TCL and both have shown durabilitiy beyond the SOC and even beyond that deemed to be a target for a registrational trial approval.
What was highlighted and given some context is the fact that "The nature of PTX-100’s efficacy observations seem unique. Other TCL drugs only achieve durability when they achieve CR, which is a rare event. By contrast, PTX-100 patients experienced durability even with PR and SD" Steven wasn't prepared to speculate on this, nor was he prepared to speculate on why the FDA granted PTX-100 the broader Orphan Drug Designation for all TCLs when PTX approached them for ODD for CTCL at the time.
The fact that TCL consists of a bunch of rare indications and AITL happens to be a type of peripheral T-cell lymphoma. It has nearly a 70% frequency rate of the Rho-A mutation, which is significant. Of the two subsets of TCL, Peripheral TCL is more aggressive than Cutaneous TCL. That to me suggests that PTX-100 warrants a separate trial for PTCL akin to a mixed label or basket study of different TCLs and that perhaps the sweet spot for the optimal dosage has yet to be identifiied for PTCL patients. I don't know, but perhaps the Ph1 ORR and CBR rates are compelling enough for the likes of Prof Miles Prince or Peter Mac to run a separate Ph2 trial in parallel to the one PTX commits to as a registrational trial.
The safety profile opens up all sorts of doors for PTX-100 including combo trials. I always get the impression that SYC is under the pump (from Top SH) to pursue the avenue which presents as the best value for money - that which will get us to the finishing line on the least possible outlay. So, we could well need the financial support to further investigate the potential of PTX-100 across the broader T-cell Lymphoma cancer group. A good problem to have but not an easy one to resolve.
- Forums
- ASX - By Stock
- PTX
- Ann: PTX-100 Spotlight Presentation
Ann: PTX-100 Spotlight Presentation, page-11
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.7¢ |
Change
0.002(4.44%) |
Mkt cap ! $37.85M |
Open | High | Low | Value | Volume |
4.6¢ | 4.9¢ | 4.6¢ | $30.29K | 637.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 65682 | 4.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.8¢ | 221710 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 65682 | 0.047 |
1 | 170999 | 0.046 |
1 | 20000 | 0.045 |
2 | 65454 | 0.044 |
1 | 70000 | 0.043 |
Price($) | Vol. | No. |
---|---|---|
0.048 | 221710 | 2 |
0.049 | 228740 | 4 |
0.050 | 236935 | 5 |
0.051 | 19607 | 1 |
0.052 | 60000 | 1 |
Last trade - 14.21pm 07/10/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |